In Brief: Smoking cessation product labeling
This article was originally published in The Tan Sheet
Executive Summary
Smoking cessation product labeling: FDA's Drug Abuse Advisory Committee will consider the issue at its June 9 meeting in the Versailles Ballroom at the Holiday Inn Bethesda, 8120 Wisconsin Ave., Bethesda, Md. ("The Tan Sheet" April 21, p. 8). The meeting will start at 8:30 a.m. with a one-hour open public hearing and is scheduled to conclude at 5:30 p.m. On June 10, the committee will discuss clinical trial design to study therapies for cocaine addiction beginning at 8:30 a.m...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning